HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE

Clinical trials for HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE explained in plain language.

Never miss a new study

Get alerted when new HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE trials appear

Sign up with your email to follow new studies for HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Cancer Drug's Real-World performance under the microscope

Disease control Not yet recruiting

This study aims to monitor the safety and effectiveness of the breast cancer drug TUKYSA in real-world medical practice in Korea. It will enroll 600 adults with advanced HER2-positive breast cancer who are starting TUKYSA treatment as prescribed by their doctor. The main goal is …

Matched conditions: HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE

Sponsor: Pfizer • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE

Get alerted when new HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE trials appear

Cancer Drug's Real-World performance under the microscope